comparemela.com

Latest Breaking News On - Mirvetuximab soravtansine - Page 1 : comparemela.com

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

02.05.2024 - - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 .

Texas
United-states
North-carolina
American
Mirvetuximab-soravtansine
Conor-richardson
Clay-siegall
Kate-sasser
Taylor-schreiber
Exchange-commission
Ono-pharmaceutical-co-ltd
Development-rd-expenses

PROs Underscore Utility of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial.

Los-angeles
California
United-states
Gottfriede-konecny
Health-jonsson-comprehensive-cancer-center
University-of-california
Department-of-gynecologic-medical-oncology
Gynecologic-medical-oncology
Jonsson-comprehensive-cancer
D
Mirvetuximab-soravtansine

Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer

Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.

Rebeccal-porter
Harvard-medical-school
Dana-farber-cancer-institute
D
Phd
Dana-farber
Mirvetuximab-soravtansine
Pembrolizumab
Endometrial-cancer

Dr Konecny on the MIRASOL trial and Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

Gottfried Konecny, MD, discusses the MIRASOL trial that evaluated mirvetuximab soravtansine in FRα-positive platinum-resistant recurrent ovarian cancer.

Los-angeles
California
United-states
Gottfried-konecny
Department-of-medicine
University-of-california
Gynecologic-oncology
Ovarian-cancer
D
Mirvetuximab-soravtansine

Modesitt Spotlights the Latest ADC Breakthroughs in Gynecologic Oncology

Susan C. Modesitt, MD, FACOG, FACS, sheds light on the latest research with antibody-drug conjugates across gynecologic cancers.

Emory-university
Georgia
United-states
Atlanta
Susanc-modesitt
National-comprehensive-cancer-network
Winship-cancer-institute-of-emory-university
Onclive-state
Science-summit
Winship-cancer-institute
Gynecologic-oncology

vimarsana © 2020. All Rights Reserved.